Mazdutide: Trials and FDA Status
Mazdutide is a glp-1/glucagon dual agonist. This page tracks its trials, sponsor and FDA status, with a dated source for each milestone.
Where it stands
- US status
- Approved in China; investigational in the US
- Phase
- Phase 3
- Sponsor
- Innovent Biologics; Eli Lilly
- Expected FDA decision
- None announced
- no primary source states a date (checked 2 Oct 2026)
- Trial IDs (NCT)
- NCT04904913, NCT05607680, NCT05606913, NCT05628311, NCT06124807
Reported results
- 2025GLORY-1 phase 3 (NEJM 2025): weight change at 48 weeks vs placebo“At week 48, the mean percentage change in body weight from baseline was -11.00% (95% CI, -12.27 to -9.73) in the 4-mg mazdutide group, -14.01% (95% CI, -15.36 to -12.66) in the 6-mg mazdutide group, and 0.30% (95% CI, -0.98 to 1.58) in the placebo group”pubmed.ncbi.nlm.nih.gov
Company-reported figures are labelled as such. Results in a trial population may not match results elsewhere.
Milestones
- FDA warning letters to five research-peptide sellersEnforcement
- Published in Nature (2026): Mazdutide versus placebo in Chinese adults with type 2 diabetes.
- Published in Nature (2026): Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.
- Published in The lancet. Diabetes & endocrinology (2026): Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.
- Innovent announces China's NMPA approved mazdutide for chronic weight management in adults with overweight or obesity
- NCT06124807 (A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight; Phase 2): primary completion
- Published in The New England journal of medicine (2025): Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.
- Innovent announces NMPA (China) acceptance of the second mazdutide NDA, for type 2 diabetes
- Innovent announces NMPA (China) acceptance of the first mazdutide NDA, for chronic weight management
- NCT05606913 (A Study of IBI362 in Participants With Type 2 Diabetes; Phase 3): primary completion
- Published in Diabetes care (2024): Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.
- NCT06124807 (A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight; Phase 2): study start
- NCT06124807 (A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight; Phase 2): first posted on ClinicalTrials.gov
- NCT05628311 (A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise; Phase 3): primary completion
- NCT05607680 (A Study of IBI362 in Participants With Obesity or Overweight; Phase 3): primary completion
- NCT04904913 (A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects; Phase 2): primary completion
- NCT05606913 (A Study of IBI362 in Participants With Type 2 Diabetes; Phase 3): study start
- NCT05628311 (A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise; Phase 3): study start
- NCT05628311 (A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise; Phase 3): first posted on ClinicalTrials.gov
- NCT05607680 (A Study of IBI362 in Participants With Obesity or Overweight; Phase 3): study start
- NCT05607680 (A Study of IBI362 in Participants With Obesity or Overweight; Phase 3): first posted on ClinicalTrials.gov
- NCT05606913 (A Study of IBI362 in Participants With Type 2 Diabetes; Phase 3): first posted on ClinicalTrials.gov
- NCT04904913 (A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects; Phase 2): study start
- NCT04904913 (A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects; Phase 2): first posted on ClinicalTrials.gov
- Published in EClinicalMedicine (2021): IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study.
What the mazdutide registry entries specify
GLORY-1 (NCT05607680) is titled as a randomised, double-blind, placebo-controlled phase III study of IBI362 in Chinese adults with obesity or overweight.[2]
GLORY-1 enrolled 610 participants.[2]
GLORY-1 is completed: it started 2022-11-14 and reached primary completion on 2023-08-21.[2]
In GLORY-1, the 6 mg arm used 2 mg for 4 weeks, 4 mg for 4 weeks and then 6 mg for 40 weeks.[2]
The US phase 2 trial (NCT06124807) enrolled 179 participants.[5]
It is completed: it started 2023-11-17 and reached primary completion on 2025-01-22.[5]
In the US trial, once-weekly mazdutide is escalated until a target dose of 16 mg is reached.[5]
Primary endpoints and trial length
GLORY-1's primary outcome is percent change in body weight from baseline to Week 32.[2]
The US trial's primary outcome is also percent change in body weight at Week 32.[5]
From start to primary completion, GLORY-1 spans 40 weeks and the US phase 2 trial 62 weeks.
Calculated from NCT05607680 start 2022-11-14, primary completion 2023-08-21, type ACTUAL; NCT06124807 start 2023-11-17, primary completion 2025-01-22, type ACTUAL. Formula: weeks = round((primary completion date - start date) / 7 days)
Published results
In GLORY-1, weight change at week 48 was -11.00% at 4 mg and -14.01% at 6 mg, against 0.30% on placebo.[9]
Adverse events led to discontinuation in 1.5% at 4 mg, 0.5% at 6 mg and 1.0% on placebo.[9]
Approval and regulatory context
Innovent's release says China's NMPA has approved mazdutide for chronic weight management in Chinese adults with overweight or obesity.[15]
Common questions
Is mazdutide FDA approved?
No. An FDA page says the agency has warned companies that illegally sold unapproved drugs containing mazdutide, among other peptides.[16]
Sources
- 1A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects (NCT04904913)ClinicalTrials.gov (U.S. National Library of Medicine) · 2021clinicaltrials.govAccessed 2 Oct 2026
- 2A Study of IBI362 in Participants With Obesity or Overweight (NCT05607680)ClinicalTrials.gov (U.S. National Library of Medicine) · 2022clinicaltrials.govAccessed 2 Oct 2026
- 3A Study of IBI362 in Participants With Type 2 Diabetes (NCT05606913)ClinicalTrials.gov (U.S. National Library of Medicine) · 2022clinicaltrials.govAccessed 2 Oct 2026
- 4A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise (NCT05628311)ClinicalTrials.gov (U.S. National Library of Medicine) · 2022clinicaltrials.govAccessed 2 Oct 2026
- 5A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight (NCT06124807)ClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
- 6FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 7IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study.EClinicalMedicine · 2021PMID 34430840Accessed 2 Oct 2026
- 8Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.Diabetes care · 2024PMID 37943529Accessed 2 Oct 2026
- 9Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.The New England journal of medicine · 2025PMID 40421736Accessed 2 Oct 2026
- 10Mazdutide versus placebo in Chinese adults with type 2 diabetes.Nature · 2026PMID 41407859Accessed 2 Oct 2026
- 11Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.Nature · 2026PMID 41407860Accessed 2 Oct 2026
- 12Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.The lancet. Diabetes & endocrinology · 2026PMID 42628555Accessed 2 Oct 2026
- 13Innovent announces NMPA (China) acceptance of the first mazdutide NDA, for chronic weight managementInnovent (press release via PR Newswire) · 2026Accessed 2 Oct 2026
- 14Innovent announces NMPA (China) acceptance of the second mazdutide NDA, for type 2 diabetesInnovent (press release via PR Newswire) · 2026Accessed 2 Oct 2026
- 15Innovent announces China's NMPA approved mazdutide for chronic weight management in adults with overweight or obesityInnovent (press release via PR Newswire) · 2026Accessed 2 Oct 2026
- 16Official web pageOfficial web page · web page
Found an error? Report a correction.